Literature DB >> 21992710

The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer.

Henry M Marshall1, Steven C Leong, Rayleen V Bowman, Ian A Yang, Kwun M Fong.   

Abstract

The Tumour, Node, Metastasis (TNM) system for classifying lung cancer is the cornerstone of modern lung cancer treatment and underpins comparative research; yet is continuously evolving through updated revisions. The recently published Union for International Cancer Control 7th Edition TNM Classification for lung cancer addresses many of its predecessor's shortcomings and has been subject to rigorous evidence-based methodology. It is based on a retrospective analysis of over 80 000 lung cancer patients treated between 1990 and 2000 carried out by the International Association for the Study of Lung Cancer. The dataset was truly international and included patients treated by all modalities. Extensive internal and external validation of the findings has ensured that the recommendations are robust and generalizable. For the first time, a single classification system has been shown to be applicable not only to non-small cell lung cancer, but also to be of prognostic significance in small cell lung cancer and bronchopulmonary carcinoid tumours. We review the history of the Union for International Cancer Control TNM staging system, the changes in the most recent 7th edition and the strength of the scientific basis motivating these changes. Limitations of the current staging edition are explored, post-publication independent validation studies are reviewed, and the future of TNM staging for lung cancer is discussed.
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Year:  2012        PMID: 21992710     DOI: 10.1111/j.1440-1843.2011.02083.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  10 in total

Review 1.  Lung cancer staging: clinical and radiologic perspectives.

Authors:  Sophie Chheang; Kathleen Brown
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

2.  The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm.

Authors:  Jingquan Han; Yuzhang Li; Shouqiang Cao; Qing Dong; Guibin Zhao; Xiangyu Zhang; Jian Cui
Journal:  Biomed Rep       Date:  2017-05-19

3.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 4.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

Review 5.  Year in review 2012: lung cancer, respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  José M Porcel; Chi Chiu Leung; Marcos I Restrepo; Kazuhisa Takahashi; Pyng Lee
Journal:  Respirology       Date:  2013-04       Impact factor: 6.424

6.  Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.

Authors:  Jinsong Li; Huayun Deng; Meichun Hu; Yuanzhang Fang; Amanda Vaughn; Xiaopan Cai; Leqin Xu; Wei Wan; Zhenxi Li; Shijie Chen; Xinghai Yang; Song Wu; Jianru Xiao
Journal:  Oncotarget       Date:  2015-03-30

Review 7.  The International Association for the Study of Lung Cancer Lymph Node Map: A Radiologic Atlas and Review.

Authors:  Jin Hwan Kim; Edwin Jr van Beek; John T Murchison; Aleksander Marin; Saeed Mirsadraee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-06-30

8.  Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters.

Authors:  Masataka Karube; Naoyoshi Yamamoto; Yoshiyuki Shioyama; Junichi Saito; Akira Matsunobu; Tamaki Okimoto; Tatsuya Ohno; Hiroshi Tsuji; Takashi Nakano; Tadashi Kamada
Journal:  J Radiat Res       Date:  2017-09-01       Impact factor: 2.724

9.  Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?

Authors:  Shoko Sonobe Shimamura; Takehito Shukuya; Tetsuhiko Asao; Daisuke Hayakawa; Kana Kurokawa; Shiting Xu; Keita Miura; Yoichiro Mitsuishi; Ken Tajima; Rina Shibayama; Naoko Shimada; Fumiyuki Takahashi; Kazuhisa Takahashi
Journal:  BMC Cancer       Date:  2022-03-25       Impact factor: 4.430

10.  Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry.

Authors:  I Re Heo; Ho Cheol Kim; Seung Jun Lee; Jung-Wan Yoo; Sunmi Ju; Yi Yeong Jeong; Jong Deog Lee; Yu Ji Cho; Jong Hwan Jeong; Manbong Heo; Seung Woo Jung; Tae Hoon Kim
Journal:  Thorac Cancer       Date:  2021-08-01       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.